BUSINESS COMBINATIONS (Details 7)	3 Months Ended		1 Months Ended	3 Months Ended
	Mar. 31, 2012 USD ($)	Mar. 31, 2011 USD ($)	Mar. 31, 2011 PharmaSwiss country area	Mar. 31, 2011 PharmaSwiss USD ($)	Mar. 31, 2012 PharmaSwiss USD ($)	Mar. 31, 2012 PharmaSwiss EUR (€)	Mar. 10, 2011 PharmaSwiss USD ($)	Mar. 10, 2011 PharmaSwiss EUR (€)	Feb. 28, 2011 PharmaSwiss EUR (€)	Mar. 31, 2012 PharmaSwiss Emerging Markets USD ($)
Business Combinations
Cash consideration							$ 491,200,000	€ 353,100,000
Maximum contingent payment							41,700,000	30,000,000
Fair value of contingent payments							27,500,000
Potential contingent consideration payment					13,000,000	10,000,000
Notional amount of foreign currency forward-exchange contract purchased									130,000,000
Gain on settlement of foreign currency forward-exchange contract				5,100,000
Foreign exchange loss recognized on amount bought to finance business acquisition				2,400,000
Remaining foreign currency consideration used to finance transaction of business combination									220,000,000
Net foreign exchange gain recognized in earnings	24,299,000	2,807,000		2,700,000
Number of therapeutic areas in which broad product portfolio is offered			7
Number of countries of operation			19
Assets acquired and liabilities assumed
Goodwill										$ 159,700,000